News & Updates
Filter by Specialty:
Treatment de-escalation safe in patients with ERBB2-positive early breast cancer and high TILs
De-escalation of chemotherapy dose and trastuzumab duration may not increase the risk of distant relapse or death in patients with ERBB2-positive (also referred to as HER2-positive) early breast cancer and tumour infiltrating lymphocyte (TIL) levels of ≥20 percent, according to a 10-year analysis of the phase III ShortHER trial.
Treatment de-escalation safe in patients with ERBB2-positive early breast cancer and high TILs
11 Mar 2025
Adjuvant nivolumab delivers in muscle-invasive bladder cancer
Adjuvant nivolumab appears to improve survival outcomes in patients with muscle-invasive bladder cancer (MIBC) who have undergone radical surgery, regardless of prior exposure to neoadjuvant chemotherapy, according to additional data from the phase III CheckMate 274 trial.
Adjuvant nivolumab delivers in muscle-invasive bladder cancer
09 Mar 2025
Survival in mCRPC prolonged with talazoparib–enzalutamide combo
The combination of the PARP inhibitor talazoparib plus the androgen receptor-pathway inhibitor enzalutamide yields a clinically meaningful increase in the overall survival of patients with metastatic castration-resistant prostate cancer (mCRPC) being treated in the first-line setting when compared with enzalutamide alone, according to final data from the phase III TALAPRO-2 trial.
